InstalabLoading...
InstalabLoading...
If you have unexplained gut symptoms, a family history of Crohn's disease, or you work around livestock and dairy, this is a marker worth knowing about. MAP (Mycobacterium avium subspecies paratuberculosis) is a slow-growing bacterium that has been found at much higher rates in the intestinal tissue and blood of people with Crohn's disease than in healthy controls.
This is a research-grade test, not a routine clinical screen. A positive result does not diagnose any single condition, but it does open a question that standard inflammatory bowel workups rarely ask: is a specific, persistent bacterium contributing to what your gut is doing?
MAP is a hardy, rod-shaped bacterium with a thick fatty cell wall that helps it survive inside the body and in the environment. It lives and multiplies primarily inside macrophages, which are the immune cells your body uses to engulf and digest microbes. In ruminants like cattle, sheep, and goats, MAP causes a chronic inflammatory bowel disease called Johne's disease, with long latent periods before symptoms appear.
In humans, MAP DNA and viable bacteria have been found in the lining of the small and large intestine, in peripheral blood, and occasionally in other tissues. The bacterium can persist in dairy products and can survive some pasteurization processes, which is one reason researchers have explored it as a possible link between livestock infection and human disease.
The strongest signal in the human literature connects MAP to Crohn's disease. In one study using a highly specific genetic test on intestinal tissue biopsies, MAP DNA was detected in 92% of Crohn's patients compared with 26% of controls without inflammatory bowel disease. Another biopsy study from Sardinia found MAP in 83% of Crohn's patients versus 10% of controls. A larger series found MAP in 52% of Crohn's tissue samples versus 2% of ulcerative colitis samples and 5% of non-IBD samples.
Blood-based detection tells a similar story. In one study, viable MAP was cultured from the blood of about half of Crohn's patients and from none of the non-IBD controls. A pooled analysis of genetic testing studies found that MAP was detected meaningfully more often in Crohn's patients than in controls, with a roughly 23 percentage point excess detection rate.
The biology behind this association is suggestive but not yet proof of cause. MAP-positive Crohn's tissue produces more TNF-alpha, an inflammatory signaling protein that is itself a major target of Crohn's drugs. The bacterium also appears to drive cellular stress, with higher activity of a selenium-dependent antioxidant enzyme called glutathione peroxidase in MAP-positive people. Whether MAP causes Crohn's, worsens it, or simply takes advantage of an already-inflamed gut is still actively debated.
A pooled analysis of studies looking at MAP and multiple sclerosis (MS) found a strong association. People with anti-MAP antibodies were roughly 11 to 13 times more likely to have MS than people without them, and people with detectable MAP DNA in their blood were about 5 times more likely. The authors flagged some publication bias in the antibody studies, so the true effect may be smaller than the headline number, but the direction was consistent.
Separate work has found that MAP-positive and MAP-negative MS patients have different gut bacterial patterns, suggesting MAP may interact with the broader microbiome to shape MS-related inflammation. MAP exposure has not been shown to cause MS, but the link is one of the more compelling environmental signals in MS research.
Antibodies to a MAP virulence protein called PtpA were found in 95% of rheumatoid arthritis (RA) patients in one study, far more often than in matched controls, and antibodies to other MAP peptides have shown similar patterns. Researchers think this may reflect molecular mimicry, where the immune system reacts to a MAP protein that resembles a human protein, but causation has not been established.
In type 1 diabetes (T1D), a pooled analysis found that anti-MAP antibodies and MAP DNA were both significantly more common in people with T1D than in controls. Children at genetic risk for T1D have shown strong immune recognition of MAP peptides that resemble human proteins involved in insulin production, again raising the molecular mimicry hypothesis.
MAP is not a clean "good number, bad number" marker. A positive result does not mean you will develop Crohn's, MS, RA, or diabetes. Healthy people can carry MAP DNA or antibodies without disease, and the bacterium can be present in food and the environment. What the evidence shows is that MAP is detected far more often in several chronic inflammatory and autoimmune conditions than in matched controls. The marker is best read as a flag for further investigation, not a diagnosis.
There are no standardized clinical reference ranges for human MAP testing. Results are typically reported as detected or not detected for genetic and culture tests, or as a positive or negative antibody response for serology. Different labs use different targets, antigens, and cutoffs, so values from one lab cannot be directly compared with another.
These illustrative detection rates come from research cohorts using genetic and culture-based methods on intestinal biopsies and blood. They are orientation, not clinical thresholds. Your lab will report a qualitative result, and the meaning depends on your symptoms and other findings.
| Population | How Often MAP Was Detected | What This Suggests |
|---|---|---|
| Crohn's disease patients (intestinal biopsy) | Roughly 39% to 92% across studies | Substantially more common than in controls, supporting an association |
| Crohn's disease patients (blood culture) | About 50% in one study | Suggests viable bacteria in circulation, rare in non-IBD |
| Non-IBD or healthy controls | Roughly 2% to 26% across studies | MAP can be present without disease; a positive alone is not diagnostic |
Source: Bull et al. 2003; Sechi et al. 2005; Autschbach et al. 2005; Naser et al. 2004.
A single MAP test result is a snapshot. The bacterium is famously hard to detect, with long latent periods and tests that can miss low-level infection. Studies in animals consistently show that even repeatedly tested negative subjects can still harbor MAP, which means a single negative result should not be read as definitive.
If you have ongoing symptoms or a strong reason to suspect MAP exposure, retesting after several months, ideally using both genetic and antibody-based methods, gives you more signal than any one reading. If you are working with a clinician on anti-MAP therapy or other interventions, serial testing is the only way to track whether the underlying biology is shifting.
A positive MAP result is not a diagnosis on its own. Pair it with a full inflammatory bowel workup, which typically includes endoscopy with biopsies, fecal calprotectin, hs-CRP (high-sensitivity C-reactive protein), and a CBC. If you have neurological symptoms or a family history of MS, share the result with a neurologist. If you have joint symptoms, share it with a rheumatologist.
For people with confirmed Crohn's disease, a positive MAP result may inform discussions about anti-mycobacterial therapy, which is being studied in clinical trials. For people without active disease, a positive result is a reason to monitor symptoms closely, optimize gut health, and consider periodic retesting alongside standard inflammatory markers.
MAP testing has real limitations, and a single result can mislead in several ways:
MAP testing sits in a different category from cholesterol or blood sugar. It does not give you a number to optimize. What it does is answer a specific question: is there evidence of a persistent bacterium in your body that has been repeatedly linked to several chronic conditions? For most healthy adults, that question may not be urgent. For people with unexplained gut symptoms, a family history of Crohn's, autoimmune disease, or significant exposure to dairy and livestock, the answer is worth having.
Evidence-backed interventions that affect your M. Avium Subspecies Paratuberculosis level
M. Avium Subspecies Paratuberculosis is best interpreted alongside these tests.